Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095
- 1 March 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 50 (5) , 787-791
Abstract
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .Keywords
This publication has 8 references indexed in Scilit:
- Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapyAIDS, 2009
- Switching from suppressive protease inhibitor‐based regimens to nevirapine‐based regimens: a meta‐analysis of randomized controlled trialsHIV Medicine, 2008
- Is it safe to switch between efavirenz and nevirapine in the event of toxicity?The Lancet Infectious Diseases, 2007
- Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 + T-cell CountsAntiviral Therapy, 2007
- Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 InfectionA Randomized Controlled TrialJAMA, 2006
- Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095Antiviral Therapy, 2006
- Switch from Efavirenz to Nevirapine Associated with Resolution of Efavirenz-Related Neuropsychiatric Adverse Events and Improvement in Lipid ProfilesAIDS Patient Care and STDs, 2006
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004